ALMDT.PA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 18:35):

Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally...

Stats
Šios dienos apimtis	139 101
Vidutinė apimtis	47 660.00
Rinkos kapitalizacija	55.68M
EPS	€0 ( 2024-04-25 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-2.04
ATR14	€0.0210 (0.77%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: -0.54 (weak negative)

Signal:(56.095) Neutral

Median Technologies SA Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Median Technologies SA Koreliacija - Valiuta/Žaliavos

-0.70
( moderate negative )

-0.72
( moderate negative )

0.00
( neutral )

-0.55
( weak negative )

-0.23
( neutral )

0.60
( weak )

Median Technologies SA Finansinės ataskaitos

Annual	2023
Pajamos:	€22.20M
Bruto pelnas:	€22.20M (100.00 %)
EPS:	€0

FY	2023
Pajamos:	€22.20M
Bruto pelnas:	€22.20M (100.00 %)
EPS:	€0

FY	2022
Pajamos:	€23.67M
Bruto pelnas:	€24.42M (103.17 %)
EPS:	€-1.280

FY	2021
Pajamos:	€20.55M
Bruto pelnas:	€20.43M (99.43 %)
EPS:	€-1.250

Financial Reports:

No articles found.

Median Technologies SA

Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiops, an end-to-end AI-powered technology software as a medical device that integrates and optimizes the entire medical imaging workflow; and iSee for image analysis services in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California. The company was founded in 2002 and is based in Valbonne, France.